Dynavax Technologies Completes Acquisition by Sanofi, Initiates Nasdaq Delisting

summarizeSummary

Dynavax Technologies announced the completion of its acquisition by Sanofi, leading to the delisting of its shares from Nasdaq and the conversion of all outstanding shares into cash at $15.50.

check_boxKey Events

• Acquisition Completed

  Sanofi's acquisition of Dynavax Technologies is complete, with Purchaser merging into Dynavax, making it an indirect wholly-owned subsidiary of Sanofi.

• Nasdaq Delisting Initiated

  The company has requested Nasdaq to halt trading and delist its shares, effective before the opening of trading on February 10, 2026, and intends to deregister its shares.

• Shares Converted to Cash

  All outstanding shares not tendered in the offer were automatically canceled and converted into the right to receive $15.50 per share in cash.

• Board and Officer Changes

  All previous directors resigned, and new directors and officers were appointed, reflecting the change in control.

auto_awesomeAnalysis

This 8-K filing confirms the definitive completion of Sanofi's acquisition of Dynavax Technologies. This event fundamentally alters the investment thesis for public shareholders, as Dynavax will cease to be an independent publicly traded entity. The delisting from Nasdaq and the conversion of all remaining shares into cash at the offer price of $15.50 mark the final stage of this major corporate transaction. The changes in the board and executive leadership, along with the termination of equity plans and adjustments to convertible notes, solidify the company's transition to a wholly-owned subsidiary. The disclosure of excise tax reimbursements for key executives provides insight into the financial arrangements for management in connection with the merger.